Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Receives $10.80 Average PT from Analysts

Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) have been assigned an average recommendation of “Moderate Buy” from the seven research firms that are currently covering the stock, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $10.80.

XERS has been the topic of several research analyst reports. Wall Street Zen raised shares of Xeris Biopharma from a “buy” rating to a “strong-buy” rating in a research note on Saturday, March 7th. Weiss Ratings upgraded shares of Xeris Biopharma from a “sell (d-)” rating to a “hold (c-)” rating in a research note on Wednesday, March 4th. HC Wainwright reissued a “buy” rating and issued a $10.00 target price on shares of Xeris Biopharma in a report on Monday, March 2nd. Finally, Barclays began coverage on Xeris Biopharma in a report on Monday, December 8th. They set an “overweight” rating and a $9.00 price target for the company.

Xeris Biopharma Stock Up 4.1%

Shares of NASDAQ XERS opened at $6.04 on Monday. The stock has a market cap of $1.04 billion, a PE ratio of -603.40 and a beta of 0.61. The business has a fifty day moving average of $6.39 and a two-hundred day moving average of $7.31. Xeris Biopharma has a 52-week low of $3.81 and a 52-week high of $10.08. The company has a debt-to-equity ratio of 16.10, a quick ratio of 1.57 and a current ratio of 2.19.

Xeris Biopharma (NASDAQ:XERS) last posted its earnings results on Monday, March 2nd. The company reported $0.06 earnings per share for the quarter, topping the consensus estimate of $0.03 by $0.03. The business had revenue of $85.81 million for the quarter, compared to analyst estimates of $86.00 million. Xeris Biopharma had a net margin of 0.19% and a negative return on equity of 5.33%. As a group, equities research analysts expect that Xeris Biopharma will post -0.41 earnings per share for the current fiscal year.

Insider Transactions at Xeris Biopharma

In related news, insider Kevin Mcculloch sold 15,000 shares of Xeris Biopharma stock in a transaction dated Thursday, January 8th. The stock was sold at an average price of $8.00, for a total value of $120,000.00. Following the completion of the transaction, the insider directly owned 1,685,426 shares of the company’s stock, valued at $13,483,408. The trade was a 0.88% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider John Patrick Shannon, Jr. sold 24,907 shares of the company’s stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $7.08, for a total transaction of $176,341.56. Following the transaction, the insider owned 2,705,346 shares in the company, valued at approximately $19,153,849.68. This trade represents a 0.91% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 89,908 shares of company stock worth $648,515. Insiders own 6.47% of the company’s stock.

Hedge Funds Weigh In On Xeris Biopharma

A number of large investors have recently modified their holdings of the stock. Kestra Advisory Services LLC acquired a new stake in shares of Xeris Biopharma in the fourth quarter valued at approximately $25,000. AlphaQuest LLC bought a new position in Xeris Biopharma in the third quarter valued at about $35,000. Caitong International Asset Management Co. Ltd raised its holdings in Xeris Biopharma by 9,276.3% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 7,501 shares of the company’s stock worth $59,000 after purchasing an additional 7,421 shares during the last quarter. Northwestern Mutual Wealth Management Co. lifted its position in Xeris Biopharma by 179.3% during the 3rd quarter. Northwestern Mutual Wealth Management Co. now owns 7,789 shares of the company’s stock valued at $63,000 after purchasing an additional 5,000 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Xeris Biopharma by 29.2% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,063 shares of the company’s stock valued at $63,000 after purchasing an additional 1,820 shares during the last quarter. 42.75% of the stock is currently owned by institutional investors and hedge funds.

About Xeris Biopharma

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.